These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11727216)

  • 1. [Microdialysis cerebral. Main application of this technique].
    Blanco-Lezcano L; Pavón-Fuentes N; Blanco-Lezcano V
    Rev Neurol; 2001 Sep 1-15; 33(5):464-70. PubMed ID: 11727216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential activation of dopamine release in the nucleus accumbens core and shell after acute or repeated amphetamine injections: a comparative study in the Roman high- and low-avoidance rat lines.
    Giorgi O; Piras G; Lecca D; Corda MG
    Neuroscience; 2005; 135(3):987-98. PubMed ID: 16154292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mapping neuronal activity of the basal ganglia in experimental models of Parkinson's disease: contributions of the [14C]2-deoxyglucose method.
    Orzi F; Fornai F; Blandini F
    Funct Neurol; 2000; 15(4):269-76. PubMed ID: 11213530
    [No Abstract]   [Full Text] [Related]  

  • 4. Peculiarities of L: -DOPA treatment of Parkinson's disease.
    Kostrzewa RM; Nowak P; Kostrzewa JP; Kostrzewa RA; Brus R
    Amino Acids; 2005 Mar; 28(2):157-64. PubMed ID: 15750845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pentobarbital inhibits L-DOPA-induced dopamine increases in the rat striatum: An in vivo microdialysis study.
    Adachi YU; Yamada S; Satomoto M; Watanabe K; Higuchi H; Kazama T; Doi M; Sato S
    Brain Res Bull; 2006 May; 69(5):593-6. PubMed ID: 16647588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cortical cholinergic deficiency enhances amphetamine-induced dopamine release in the accumbens but not striatum.
    Mattsson A; Olson L; Svensson TH; Schilström B
    Exp Neurol; 2007 Nov; 208(1):73-9. PubMed ID: 17714706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different function of pedunculopontine GABA and glutamate receptors in nucleus accumbens dopamine, pedunculopontine glutamate and operant discriminative behavior.
    Steiniger-Brach B; Kretschmer BD
    Eur J Neurosci; 2005 Oct; 22(7):1720-30. PubMed ID: 16197512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of ketanserin and amphetamine on nigrostriatal neurotransmission and reactive oxygen species in Parkinsonian rats. In vivo microdialysis study.
    Nowak P; Szczerbak G; Biedka I; Drosik M; Kostrzewa RM; Brus R
    J Physiol Pharmacol; 2006 Dec; 57(4):583-97. PubMed ID: 17229983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective stimulation of serotonin2c receptors blocks the enhancement of striatal and accumbal dopamine release induced by nicotine administration.
    Di Matteo V; Pierucci M; Esposito E
    J Neurochem; 2004 Apr; 89(2):418-29. PubMed ID: 15056285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine responsiveness to drugs of abuse: A shell-core investigation in the nucleus accumbens of the mouse.
    Zocchi A; Girlanda E; Varnier G; Sartori I; Zanetti L; Wildish GA; Lennon M; Mugnaini M; Heidbreder CA
    Synapse; 2003 Dec; 50(4):293-302. PubMed ID: 14556234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the effects of deramciclane, ritanserin and buspirone on extracellular dopamine and its metabolites in striatum and nucleus accumbens of freely moving rats.
    Kääriäinen TM; Lehtonen M; Forsberg MM; Savolainen J; Käenmäki M; Männistö PT
    Basic Clin Pharmacol Toxicol; 2008 Jan; 102(1):50-8. PubMed ID: 17971064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inverse relationship between brain noradrenaline level and dopamine loss in Parkinson disease: a possible neuroprotective role for noradrenaline.
    Tong J; Hornykiewicz O; Kish SJ
    Arch Neurol; 2006 Dec; 63(12):1724-8. PubMed ID: 17172611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The rotational model and microdialysis: Significance for dopamine signalling, clinical studies, and beyond.
    Herrera-Marschitz M; Arbuthnott G; Ungerstedt U
    Prog Neurobiol; 2010 Feb; 90(2):176-89. PubMed ID: 20185033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic treatment with a dopamine uptake blocker changes dopamine and acetylcholine but not glutamate and GABA concentrations in prefrontal cortex, striatum and nucleus accumbens of the awake rat.
    Hernández LF; Segovia G; Mora F
    Neurochem Int; 2008 Feb; 52(3):457-69. PubMed ID: 17881090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of metaquant microdialysis for measurement of absolute concentrations of amphetamine and dopamine in brain: a viable method for assessing pharmacokinetic profile of drugs in the brain.
    Sood P; Cole S; Fraier D; Young AM
    J Neurosci Methods; 2009 Dec; 185(1):39-44. PubMed ID: 19747947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in dopamine responsiveness to drugs of abuse in the nucleus accumbens shell and core of Lewis and Fischer 344 rats.
    Cadoni C; Di Chiara G
    J Neurochem; 2007 Oct; 103(2):487-99. PubMed ID: 17666048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sparing of behavior and basal extracellular dopamine after 6-hydroxydopamine lesions of the nigrostriatal pathway in rats exposed to a prelesion sensitizing regimen of amphetamine.
    Moroz IA; Peciña S; Schallert T; Stewart J
    Exp Neurol; 2004 Sep; 189(1):78-93. PubMed ID: 15296838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired acquisition of skilled behavior in rotarod task by moderate depletion of striatal dopamine in a pre-symptomatic stage model of Parkinson's disease.
    Ogura T; Ogata M; Akita H; Jitsuki S; Akiba L; Noda K; Hoka S; Saji M
    Neurosci Res; 2005 Mar; 51(3):299-308. PubMed ID: 15710494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa in the treatment of Parkinson's disease: current controversies.
    Olanow CW; Agid Y; Mizuno Y; Albanese A; Bonuccelli U; Damier P; De Yebenes J; Gershanik O; Guttman M; Grandas F; Hallett M; Hornykiewicz O; Jenner P; Katzenschlager R; Langston WJ; LeWitt P; Melamed E; Mena MA; Michel PP; Mytilineou C; Obeso JA; Poewe W; Quinn N; Raisman-Vozari R; Rajput AH; Rascol O; Sampaio C; Stocchi F
    Mov Disord; 2004 Sep; 19(9):997-1005. PubMed ID: 15372588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of functional D2 receptors prevents the effects of the D3-preferring agonist (+)-PD 128907 on dialysate dopamine levels.
    Zapata A; Shippenberg TS
    Neuropharmacology; 2005 Jan; 48(1):43-50. PubMed ID: 15617726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.